Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Drugs ; 81(7): 771-823, 2021 May.
Article in English | MEDLINE | ID: mdl-33788182

ABSTRACT

The proliferation of targeted anticancer agents over the last two decades has revolutionized cancer treatment and improved survival in many previously refractory malignancies. However, many agents are associated with characteristic ophthalmic adverse effects. It is important that ophthalmologists recognize and maintain a high index of suspicion for these side effects in patients on targeted therapy. Most ophthalmic adverse effects can be treated with specific ocular therapy without discontinuation of cancer treatment, although it is important to be aware of the life-threatening and vision-threatening circumstances that would require therapy cessation in conjunction with the patient's oncologist. This review aims to summarize the ophthalmic adverse effects of targeted and hormonal anticancer agents and briefly describe their management.


Subject(s)
Antineoplastic Agents, Hormonal/adverse effects , Antineoplastic Agents, Immunological/adverse effects , Eye/drug effects , Toxic Optic Neuropathy/epidemiology , Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors , Anaplastic Lymphoma Kinase/antagonists & inhibitors , Antineoplastic Agents, Hormonal/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Aromatase Inhibitors/adverse effects , Clinical Trials as Topic , ErbB Receptors/antagonists & inhibitors , Fusion Proteins, bcr-abl/antagonists & inhibitors , Humans , Immune Checkpoint Inhibitors/adverse effects , Janus Kinase 2/antagonists & inhibitors , Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors , Phosphoinositide-3 Kinase Inhibitors/adverse effects , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Receptor Protein-Tyrosine Kinases/antagonists & inhibitors , Receptor, ErbB-2/antagonists & inhibitors , Receptors, Fibroblast Growth Factor/antagonists & inhibitors , Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors , Selective Estrogen Receptor Modulators/adverse effects , Severity of Illness Index , fms-Like Tyrosine Kinase 3/antagonists & inhibitors
2.
Recent Pat Antiinfect Drug Discov ; 15(2): 113-118, 2020.
Article in English | MEDLINE | ID: mdl-32814539

ABSTRACT

BACKGROUND: On 11th March 2020, WHO announced novel coronavirus infectious (COVID-19) as a pandemic. New Coronavirus Pneumonia (NCP) that emerge on 31st December 2019 from China and quickly became a Public Health Emergency of International Concern (PHEIC). In the absence of evidence-based proven prophylactic or therapeutic options, chloroquine/hydroxychloroquine (CQ/HCQ) patented as first line choice in COVID- 19 treatment, which raised concerns about drug poisoning, especially ocular toxicity. OBJECTIVE: This study aims to investigate the possibility of ocular toxicity and the need for ophthalmic counseling to prescribing this therapeutic protocol. METHODS: All the articles that were most relevant to the COVID-19 therapeutic or prophylactic options and CQ derivative ocular toxicity, were founded by a literature search and were thoroughly reviewed. RESULTS: Anecdotal recent reports introduce CQ/HCQ as an effective therapeutic or prophylactic choice for COVID-19. Because of the short time prescribe and the insignificant cumulative dose of the drug on the one hand and a higher risk of cross-infection during an ophthalmic examination, on the other hand, an ophthalmologic consult is not recommended except in highrisk patients for retinal toxicity. CONCLUSION: This study recommended ophthalmic evaluation before CQ/HCQ prescription for treatment or prophylaxis of COVID-19 only in preexisting maculopathy.


Subject(s)
COVID-19 Drug Treatment , COVID-19/epidemiology , Hydroxychloroquine/administration & dosage , Hydroxychloroquine/adverse effects , Toxic Optic Neuropathy/epidemiology , Toxic Optic Neuropathy/prevention & control , Animals , COVID-19/diagnosis , Chloroquine/administration & dosage , Chloroquine/adverse effects , Humans , Pre-Exposure Prophylaxis , Toxic Optic Neuropathy/diagnosis
3.
Bull Cancer ; 106(12): 1160-1176, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31757405

ABSTRACT

Radiation induced optic neuropathy (RION) is a rare but disastrous complication of radiation therapy in treatment of periorbital tumors. The objective of this study is to investigate the incidence of RION in series of patients treated from peri orbital tumors by recent photon and proton irradiation modalities. We searched the Pub Med database for studies in periorbital tumors including base of skull, sinonasal, pituitary, nasopharyngeal tumors and craniopharyngioma treated with Intensity modulated radiotherapy (IMRT) and with proton beam therapy (PBT) between 1992 and 2017 excluding metastatic tumors, lymphomas, pediatric series, those treated mainly with chemotherapy, target therapy and those written in languages other than English and French. The result retrieved 421 articles that were revised by the panel. Fourteen articles with IMRT and 27 with PBT reported usable data for the review from which 31studies that had pointed to the doses to the optic nerve (ON) and/or optic chiasm (OC) and incidence of RION have been analyzed. We have found that the incidence of RION had been reported fairly in both modalities and many other factors related to the patient, tumor, and irradiation process interplay in its development. We have concluded that proper treatment planning, good selection of treatment modality, adherence to dose constraints applied to critical structures all along with regular oncological and ophthalmological follow up, control of co-morbidities and early intervention, could help reducing its magnitude.


Subject(s)
Proton Therapy/adverse effects , Radiation Injuries/complications , Radiotherapy, Intensity-Modulated/adverse effects , Toxic Optic Neuropathy/etiology , Adenoma/radiotherapy , Craniopharyngioma/radiotherapy , Humans , Incidence , Nasopharyngeal Neoplasms/radiotherapy , Nose Neoplasms/radiotherapy , Paranasal Sinus Neoplasms/radiotherapy , Pituitary Neoplasms/radiotherapy , Skull Base Neoplasms/radiotherapy , Toxic Optic Neuropathy/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL